BREAKING: Ousted HHS Director Dr. Rick Bright files whistleblower complaint

Dr. Rick Bright, the ousted director of the office involved in developing a coronavirus vaccine, has formally filed an extensive whistleblower complaint today alleging his early warnings about the coronavirus were ignored.

He also alleges he was reassigned to a lesser role because he resisted political pressure to allow widespread use of hydroxychloroquine, a malaria drug favored by Trump.

CBS News reports Dr. Rick Bright, the vaccine expert who said he was removed from his position at the Health and Human Services Department after he tried to limit COVID-19 treatments touted by President Trump, filed a whistleblower complaint Tuesday.

The complaint says he was removed as director of Biomedical Advance Research and Development Authority soon after the publication of an article about chloroquine for which Bright admits he was a source.

“Dr. Bright opposed the broad use of chloroquine and hydroxychloroquine as lacking scientific merit, even though the Administration promoted it as a panacea and demanded that New York and New Jersey be ‘flooded’ with these drugs, which were imported from factories in Pakistan and India that had not been inspected by the FDA,” the complaint reads.

“Dr. Bright felt an urgent and compelling need to inform the American public that there was insufficient scientific data to support the use of these drugs for COVID-19 patients — particularly given their importation from factories abroad that had not been inspected by the FDA.”

Government officials, he said, “refused to listen,” so Bright opted to talk to a journalist. According to the complaint, he believed that he had a moral obligation to do what he could to protect the public “from drugs which he believed constituted a substantial and specific danger to public health and safety.”

The documents provided to the journalist were “not privileged or classified,” according to the complaint.

Soon after the article about chloroquine was published, HHS Secretary Alex Azar and Bright’s supervisor, Dr. Robert Kadlec, assistant secretary for preparedness and response, removed him as BARDA director “because they suspected he was the source,” the complaint says.

Mr. Trump has referred to hydroxychloroquine as a potential “game-changer” in treating COVID-19 and has recommended the use of the antimalarial drug as a potential treatment, despite limited evidence of the drug’s efficacy.

In mid-April, the Trump administration granted chloroquine an Emergency Use Authorization, an FDA authority that allows unapproved medical products to be used in medical emergencies. HHS political leadership directed Bright to implement he directive.

The FDA on April 24 cautioned against the use of hydroxychloroquine or chloroquine “outside of the hospital setting or a clinical trial.” The agency said it is “aware of reports of serious heart rhythm problems in patients with COVID-19” when treated with the drugs, and that they have not been shown to be “safe and effective for treating or preventing COVID-19.”

Now at the National Institutes of Health in a role he considers to have less impact, Bright is hoping he can be reinstated as BARDA’s director and resume his work on COVID-19 “without further political pressure or distractions.”

The complaint from Bright details his efforts to warn top officials about the growing threat of the coronavirus. Bright said he and other public health officials first became aware of the threat in early January 2020, and of the need to obtain information from those infected.

The information was “absolutely critical” to developing diagnostic tools and medicines to combat the coronavirus, Bright says in his complaint, but he alleges he “encountered indifference which then developed into hostility from HHS leadership,” including Azar.

Bright also detailed his efforts to warn the administration of the urgent need to secure N95 masks. On January 21, Bright said he received an email from Mike Bowen, the co-owner of the U.S.-based surgical mask producer Prestige Ameritech, offering to help the government procure masks. He shared the email with others at the agency, including Kadlec. “HHS failed to act yet again to address this impending emergency,” Bright’s complaint states.

Bright’s complaint details several clashes he had with Kadlec, who is in charge of the Strategic National Stockpile.

Read more here.